Spinning off Small Companies
This article was originally published in Start Up
Executive Summary
The post-merger cutting room floor creates a great source of new companies and products--it’s good asset management for Big Pharma, and it’s good for medical entrepreneurs. But culturally and structurally, most large companies just can’t go along with the business logic of spin-offs. Technology that does get spun off is most often completely peripheral to the parent’s business--e.g., in vitro diagnostic applications or software and equipment systems from a drug company.
You may also be interested in...
The Resurrection of Affymax
A group of venture firms decided to buy Affymax from GSK at a bargain-basement valuation. They felt it had not merely the makings of a product company but could jumpstart the creation of a fully integrated biology/screening/chemistry drug discovery company. In effect, they bought, at a discount, a proto-Vertex that wouldn't have to wait nearly a decade to see a valuation explosion.
Schering Lets Metagen Flex Its Muscles
By spinning off 50% of Metagen, Schering gets an opportunity to concentrate on near-term projects, leaving Metagen free to seek funding for its early stage research from other partners
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?
Need a specific report? 1000+ reports available
Buy Reports